Vaccine Discovery Articles & Analysis
10 news found
Creative Diagnostics works with scientists in industry and academia to support the early stages of antimicrobial, vaccine and diagnostic discovery and to advance research in bacterial infections. ...
Service Range MHC Neoepitopes Discovery For the development of therapeutic cancer vaccines and T-cell therapies, as well as an ever-growing neoepitope dataset for client program development, immunogenic neoepitopes are selected, characterized, and monitored in studies. Cancer Vaccine Development Based on pMHC Cancer vaccines to ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS ...
In an oral presentation within the track “AMR & Bacterial Vaccines”, chaired by Dr Jan Poolman (Bacterial Vaccine Discovery and Early Development, Janssen), Dr. ...
The data confirm the potential of V-306 for prophylaxis against Respiratory Syncytial Virus (RSV) infection, possibly using a convenient needle-free method of vaccination. Despite the substantial health and economic burden caused by RSV-associated illness, no vaccine is available. The first of two manuscripts has been published in "NPJ Vaccines" ...
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. ...
ByEnterome
Knocking out all strains of the targeted virus with one swift strike—a universal vaccine—is the necessary approach. At EnGen Bio, we believe the development of a universal vaccine for type A flu is in sight. ...
Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs. Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, recombinant subunit ...
Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially life-saving COVID-19 vaccine. Neovii will work in close collaboration with a team of scientists led by Prof. ...